SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Andrew Siderowf, Bridging the credibility gap in cost effectiveness analysis, Movement Disorders, 2014, 29, 2
  2. 2
    Cheng-long Xie, Wen-Wen Wang, Su-fang Zhang, Jing Gan, Zhen-Guo Liu, Continuous dopaminergic stimulation (CDS)-based treatment in Parkinson's disease patients with motor complications: A systematic review and meta-analysis, Scientific Reports, 2014, 4,

    CrossRef

  3. 3
    Chandana Buddhala, Meghan C. Campbell, Joel S. Perlmutter, Paul T. Kotzbauer, Correlation Between Decreased CSF α-Synuclein and Aβ1-42 in Parkinson Disease, Neurobiology of Aging, 2014,

    CrossRef

  4. 4
    Tejas Sankar, Nir Lipsman, Andres M. Lozano, Deep Brain Stimulation for Disorders of Memory and Cognition, Neurotherapeutics, 2014, 11, 3, 527

    CrossRef

  5. 5
    Paul S. Larson, Deep Brain Stimulation for Movement Disorders, Neurotherapeutics, 2014, 11, 3, 465

    CrossRef

  6. 6
    A. Park, D. Zid, J. Russell, A. Malone, A. Rendon, A. Wehr, X. Li, Effects of a formal exercise program on Parkinson's disease: A pilot study using a delayed start design, Parkinsonism & Related Disorders, 2014, 20, 1, 106

    CrossRef

  7. 7
    Xiao-Li Wang, Gui-Hua Xing, Bo Hong, Xiao-Ming Li, Yu Zou, Xiao-Jie Zhang, Miao-Xian Dong, Gastrodin prevents motor deficits and oxidative stress in the MPTP mouse model of Parkinson's disease: Involvement of ERK1/2–Nrf2 signaling pathway, Life Sciences, 2014,

    CrossRef

  8. 8
    Erwin E. H. van Wegen, Mark A. Hirsch, Marijn Huiskamp, Gert Kwakkel, Harnessing Cueing Training for Neuroplasticity in Parkinson Disease, Topics in Geriatric Rehabilitation, 2014, 30, 1, 46

    CrossRef

  9. 9
    Cecilia Davis, Jeremy Mudd, Meredith Hawkins, Neuroprotective effects of leptin in the context of obesity and metabolic disorders, Neurobiology of Disease, 2014,

    CrossRef

  10. 10
    Mark A. Hirsch, Mohammed Sanjak, Danielle Englert, Sanjay Iyer, Margaret M. Quinlan, Parkinson patients as partners in care, Parkinsonism & Related Disorders, 2014, 20, S174

    CrossRef

  11. 11
    Chava Peretz, Orly Chillag-Talmor, Shai Linn, Tanya Gurevich, Baruch El-Ad, Barbara Silverman, Nurit Friedman, Nir Giladi, Parkinson's disease patients first treated at age 75 years or older: A comparative study, Parkinsonism & Related Disorders, 2014, 20, 1, 69

    CrossRef

  12. 12
    A. Garcia-Cazorla, S. T. Duarte, Parkinsonism and inborn errors of metabolism, Journal of Inherited Metabolic Disease, 2014, 37, 4, 627

    CrossRef

  13. 13
    Arturo Benitez, Heather Edens, Jesse Fishman, Kimberly Moran, Mahnaz Asgharnejad, Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome, Annals of the New York Academy of Sciences, 2014, 1322, 1
  14. 14
    Michal Lubomski, R. Louise Rushworth, Will Lee, Kelly L. Bertram, David R. Williams, Sex differences in Parkinson’s disease, Journal of Clinical Neuroscience, 2014, 21, 9, 1503

    CrossRef

  15. 15
    A. Zara Herskovits, Leonard Guarente, SIRT1 in Neurodevelopment and Brain Senescence, Neuron, 2014, 81, 3, 471

    CrossRef

  16. 16
    T. L. Pitcher, M. R. MacAskill, T. J. Anderson, Trends in Antiparkinsonian Medication Use in New Zealand: 1995–2011, Parkinson's Disease, 2014, 2014, 1

    CrossRef

  17. 17
    Katherine L. Baquerizo Nole, Elizabeth Yim, Freya Van Driessche, Jeffrey M. Davidson, Manuela Martins-Green, Chandan K. Sen, Marjana Tomic-Canic, Robert S. Kirsner, Wound research funding from alternative sources of federal funds in 2012, Wound Repair and Regeneration, 2014, 22, 3
  18. 18
    Suneil K. Kalia, Tejas Sankar, Andres M. Lozano, Deep brain stimulation for Parkinsonʼs disease and other movement disorders, Current Opinion in Neurology, 2013, 26, 4, 374

    CrossRef

  19. 19
    Paul H Gordon, The murky path to drug discovery in ALS becomes clearer, The Lancet Neurology, 2013, 12, 11, 1037

    CrossRef